1
|
Tabata K, Nishie A, Shimomura Y, Isoda T, Kitamura Y, Nakata K, Yamada Y, Oda Y, Ishigami K, Baba S. Prediction of pathological response to preoperative chemotherapy for pancreatic ductal adenocarcinoma using 2-[ 18F]-fluoro-2-deoxy-d-glucose positron-emission tomography. Clin Radiol 2022; 77:436-442. [PMID: 35410786 DOI: 10.1016/j.crad.2022.03.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2021] [Accepted: 03/02/2022] [Indexed: 12/24/2022]
Abstract
AIM To determine whether the pathological response to preoperative chemotherapy for pancreatic ductal adenocarcinoma (PDAC) can be predicted using 2-[18F]-fluoro-2-deoxy-d-glucose positron-emission tomography (F-18 FDG-PET). MATERIALS AND METHODS Twenty-eight patients with PDAC who underwent only neoadjuvant chemotherapy (NAC) before surgery were enrolled in the study. All patients had F-18 FDG-PET examinations before NAC. The resected specimen was pathologically evaluated according to the Classification of Pancreatic Carcinoma (7th edn). Patients were categorised into a non-response group and a response group based on the pathological findings. The non-response group (Grades 1a and 1b) showed ≤50% necrosis in the specimen, while the specimens of the response group (Grades 2-3) showed >50% necrosis. The maximum standardised uptake values (SUVmax) of the tumours on F-18 FDG-PET were measured. The mean values of SUVmax were compared between the two groups. The diagnostic performance of SUVmax in distinguishing the two groups was also evaluated using receiver operating characteristic analysis. RESULTS The mean SUVmax of the response group was higher than that of the non-response group (9.00 ± 1.78 versus 4.26 ± 2.35; p<0.001). The optimal cut-off value of SUVmax was 9.28 for distinguishing the two groups. The sensitivity, specificity, and accuracy for the prediction in the response group were 80%, 95.7%, and 92.9%, respectively. CONCLUSIONS SUVmax on F-18 FDG-PET may be useful as a biomarker to predict the pathological response to NAC in patients with PDAC.
Collapse
Affiliation(s)
- K Tabata
- Department of Clinical Radiology, Graduate School of Medical Sciences, Kyushu University, 3-1-1, Maidashi, Higashi-ku Fukuoka, 812-8582, Japan
| | - A Nishie
- Department of Radiology Informatics and Network, Graduate School of Medical Sciences, Kyushu University, 3-1-1, Maidashi, Higashi-ku Fukuoka, 812-8582, Japan; Department of Radiology, Graduate School of Medical Science, University of the Ryukyus, 207, Uehara, Nishihara-cho, Okinawa, 903-0215, Japan.
| | - Y Shimomura
- Department of Clinical Radiology, Graduate School of Medical Sciences, Kyushu University, 3-1-1, Maidashi, Higashi-ku Fukuoka, 812-8582, Japan
| | - T Isoda
- Department of Clinical Radiology, Graduate School of Medical Sciences, Kyushu University, 3-1-1, Maidashi, Higashi-ku Fukuoka, 812-8582, Japan
| | - Y Kitamura
- Department of Clinical Radiology, Graduate School of Medical Sciences, Kyushu University, 3-1-1, Maidashi, Higashi-ku Fukuoka, 812-8582, Japan
| | - K Nakata
- Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, 3-1-1, Maidashi, Higashi-ku Fukuoka, 812-8582, Japan
| | - Y Yamada
- Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, 3-1-1, Maidashi, Higashi-ku Fukuoka, 812-8582, Japan
| | - Y Oda
- Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, 3-1-1, Maidashi, Higashi-ku Fukuoka, 812-8582, Japan
| | - K Ishigami
- Department of Clinical Radiology, Graduate School of Medical Sciences, Kyushu University, 3-1-1, Maidashi, Higashi-ku Fukuoka, 812-8582, Japan
| | - S Baba
- Department of Clinical Radiology, Graduate School of Medical Sciences, Kyushu University, 3-1-1, Maidashi, Higashi-ku Fukuoka, 812-8582, Japan
| |
Collapse
|
2
|
Oda Y, Yoshida K, Kawano R, Yoshinaka T, Oda A, Takahashi T, Oue K, Mukai A, Irifune M, Okada Y. Effects of antipsychotics on intravenous sedation with midazolam and propofol during dental treatment for patients with intellectual disabilities. J Intellect Disabil Res 2022; 66:323-331. [PMID: 35040230 DOI: 10.1111/jir.12913] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/01/2021] [Revised: 12/16/2021] [Accepted: 12/23/2021] [Indexed: 06/14/2023]
Abstract
BACKGROUND Some patients with intellectual disabilities (ID) are prescribed antipsychotic drugs for symptomatic treatment of behavioural disorders. Nevertheless, it can still prove difficult to perform dental treatments safely for some patients with ID. In such cases, treatment under intravenous sedation (IVS) is one option. Sedative, hypnotic and α-blocking effects of antipsychotic drugs may cause adverse events, such as severe hypotension, among patients who take antipsychotic drugs regularly. This study aimed to investigate the effects of oral antipsychotic medication on cardiovascular function during IVS. Accordingly, we compared mean blood pressure (MBP) and heart rate (HR) between patients who regularly take antipsychotic drugs and patients who do not. METHODS Thirty-seven patients with ID were enrolled in this study. All participants were outpatients of Special Care Dentistry of general hospital and received dental treatment under IVS performed with a combination of midazolam and propofol. Eighteen patients regularly took antipsychotics (medication group), and 19 patients were not currently taking antipsychotics (non-medication group). MBP, HR, dose, and effect-site concentration of intravenous sedative medications were measured at three points: 'before IVS', 'at optimal sedation', and 'during dental treatment'. RESULTS The magnitude of reduction of MBP was significantly smaller in the medication group than in the non-medication group (P < 0.023). However, there were no differences in MBP, HR, dose, and effect-site concentration of midazolam and propofol between groups at any point. CONCLUSION These results suggest that antipsychotic medication may not have clinically significant adverse effects on cardiovascular fluctuations during dental treatment under IVS for persons with ID.
Collapse
Affiliation(s)
- Y Oda
- Department of Special Care Dentistry, Hiroshima University Hospital, Hiroshima, Japan
| | - K Yoshida
- Department of Anesthesiology, Osaka Dental University Hospital, Osaka, Japan
| | - R Kawano
- Clinical Research Center in Hiroshima, Hiroshima University Hospital, Hiroshima, Japan
| | - T Yoshinaka
- Department of Dental Anesthesiology, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
| | - A Oda
- Department of Dental Anesthesiology, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
| | - T Takahashi
- Department of Dental Anesthesiology, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
| | - K Oue
- Department of Dental Anesthesiology, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
| | - A Mukai
- Department of Dental Anesthesiology, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
| | - M Irifune
- Department of Dental Anesthesiology, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
| | - Y Okada
- Department of Special Care Dentistry, Hiroshima University Hospital, Hiroshima, Japan
| |
Collapse
|
3
|
Onishi T, Shimonishi N, Takeyama M, Furukawa S, Ogiwara K, Nakajima Y, Kasahara K, Nishio K, Yoshimoto K, Inoue S, Kawaguchi M, Fukushima H, Saito Y, Yoshiji H, Muro S, Tsuruya K, Okada S, Sugie K, Kawaguchi R, Nishikubo T, Yamazaki M, Oda Y, Kawabe T, Onishi K, Nishio T, Nogami K. The balance of comprehensive coagulation and fibrinolytic potential is disrupted in patients with moderate to severe COVID-19. Int J Hematol 2022; 115:826-837. [PMID: 35171446 PMCID: PMC8852977 DOI: 10.1007/s12185-022-03308-w] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2021] [Revised: 02/07/2022] [Accepted: 02/07/2022] [Indexed: 12/19/2022]
Abstract
Coagulation and fibrinolytic mechanisms are enhanced in patients with coronavirus (COVID-19), but disturbances in the balance of both functions in COVID-19 patients remain unclear. We assessed global coagulation and fibrinolysis in plasma from 167 COVID-19 patients (mild/moderate/severe: 62/88/17, respectively) on admission using clot-fibrinolysis waveform analysis (CFWA). Maximum coagulation velocity (|min1|) and maximum fibrinolysis velocity (|FL-min1|) were expressed as ratios relative to normal plasma. Ten patients (6.0%) developed thrombosis, 5 (3.0%) had bleeding tendency, and 13 (7.8%) died during admission. FDP levels increased with severity of COVID-19 symptoms (mild/moderate/severe; median 2.7/4.9/9.9 μg/mL, respectively). The |min1| ratios were elevated in all categories (1.27/1.61/1.58) in keeping with enhanced coagulation potential, with significant differences between mild cases and moderate to severe cases. The |FL-min1| ratios were also elevated in all groups (1.19/1.39/1.40), reflecting enhanced fibrinolytic potential. These data identified coagulation dominance in moderate to severe cases, but balanced coagulation and fibrinolysis in mild cases. There were significant differences in FDP and TAT, but no significant differences in |min1| or |FL-min1| ratios, between patients with and without thrombosis. CFWA monitoring of coagulation and fibrinolysis dynamics could provide valuable data for understanding hemostatic changes and disease status in COVID-19 patients.
Collapse
Affiliation(s)
- Tomoko Onishi
- Department of Pediatrics, Nara Medical University, 840 Shijo-cho, Kashihara, Nara, 634-8522, Japan
| | - Naruto Shimonishi
- Department of Pediatrics, Nara Medical University, 840 Shijo-cho, Kashihara, Nara, 634-8522, Japan
| | - Masahiro Takeyama
- Department of Pediatrics, Nara Medical University, 840 Shijo-cho, Kashihara, Nara, 634-8522, Japan.
| | - Shoko Furukawa
- Department of Pediatrics, Nara Medical University, 840 Shijo-cho, Kashihara, Nara, 634-8522, Japan
| | - Kenichi Ogiwara
- Department of Pediatrics, Nara Medical University, 840 Shijo-cho, Kashihara, Nara, 634-8522, Japan
| | - Yuto Nakajima
- Department of Pediatrics, Nara Medical University, 840 Shijo-cho, Kashihara, Nara, 634-8522, Japan
| | - Kei Kasahara
- Center for Infectious Diseases, Nara Medical University, Kashihara, Japan
| | - Kenji Nishio
- Department of General Medicine, Nara Medical University, Kashihara, Japan
| | - Kiyomi Yoshimoto
- Department of General Medicine, Nara Medical University, Kashihara, Japan
| | - Satoki Inoue
- Department of Anesthesiology, Nara Medical University, Kashihara, Japan
| | | | - Hidetada Fukushima
- Emergency and Critical Care Medicine, Nara Medical University, Kashihara, Japan
| | - Yoshihiko Saito
- Department of Cardiovascular Medicine, Nara Medical University, Kashihara, Japan
| | - Hitoshi Yoshiji
- Department of Gastroenterology, Nara Medical University, Kashihara, Japan
| | - Shigeo Muro
- Department of Respiratory Medicine, Nara Medical University, Kashihara, Japan
| | - Kazuhiko Tsuruya
- Department of Nephrology, Nara Medical University, Kashihara, Japan
| | - Sadanori Okada
- Department of Diabetes and Endocrinology, Nara Medical University, Kashihara, Japan
| | - Kazuma Sugie
- Department of Neurology, Nara Medical University, Kashihara, Japan
| | - Ryuji Kawaguchi
- Department of Obstetrics and Gynecology, Nara Medical University, Kashihara, Japan
| | - Toshiya Nishikubo
- Neonatal Intensive Care Unit, Nara Medical University, Kashihara, Japan
| | - Masaharu Yamazaki
- Central Clinical Laboratory, Nara Medical University Hospital, Kashihara, Japan
| | - Yukio Oda
- SEKISUI MEDICAL CO., LTD, Tokyo, Japan
| | | | | | | | - Keiji Nogami
- Department of Pediatrics, Nara Medical University, 840 Shijo-cho, Kashihara, Nara, 634-8522, Japan
| |
Collapse
|
4
|
Fukushima K, Akagi K, Kondoh A, Kubo T, Ito Y, Oda Y, Nagihara Y, Sakamoto N, Mukae H. Evaluation of QFT-Plus performance using blood samples stored at room temperature. Int J Tuberc Lung Dis 2021; 25:948-949. [PMID: 34686239 DOI: 10.5588/ijtld.21.0319] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Affiliation(s)
- K Fukushima
- Department of Respiratory Medicine, Japanese Red Cross Nagasaki Genbaku Isahaya Hospital, Nagasaki, Japan
| | - K Akagi
- Department of Respiratory Medicine, Japanese Red Cross Nagasaki Genbaku Isahaya Hospital, Nagasaki, Japan
| | - A Kondoh
- Department of Respiratory Medicine, Japanese Red Cross Nagasaki Genbaku Isahaya Hospital, Nagasaki, Japan
| | - T Kubo
- Department of Laboratory Medicine, Japanese Red Cross Nagasaki Genbaku Isahaya Hospital, Nagasaki, Japan
| | - Y Ito
- Department of Laboratory Medicine, Japanese Red Cross Nagasaki Genbaku Isahaya Hospital, Nagasaki, Japan
| | - Y Oda
- Department of Laboratory Medicine, Japanese Red Cross Nagasaki Genbaku Isahaya Hospital, Nagasaki, Japan
| | - Y Nagihara
- Department of Laboratory Medicine, Japanese Red Cross Nagasaki Genbaku Isahaya Hospital, Nagasaki, Japan
| | - N Sakamoto
- Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
| | - H Mukae
- Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
| |
Collapse
|
5
|
Toyokawa G, Kodama M, Haratake N, Yamada Y, Kittaka H, Takenaka T, Tanaka K, Shimokawa M, Yamazaki K, Takeo S, Okamoto I, Oda Y, Nakayama K. 1662P Comprehensive analysis of the metabolic enzymes in patients with small cell lung cancer using a large-scale targeted proteomics assay. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.246] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
6
|
Oda Y, Wong C, Oh D, Meyer M, Pike J, Bikle D. 175 Dynamic transcriptional and epigenetic regulation through vitamin D receptor and p63/p53 signaling in epidermal keratinocytes. J Invest Dermatol 2021. [DOI: 10.1016/j.jid.2021.02.195] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
7
|
Shimonishi N, Ogiwara K, Oda Y, Kawabe T, Emmi M, Shima M, Nogami K. Inhibitor Index in the Clot Waveform Analysis-Based Mixing Test Differentiates among Hemophilia A without and with Inhibitors, and Lupus Anticoagulant. Thromb Haemost 2021; 121:792-799. [PMID: 33412612 DOI: 10.1055/s-0040-1721776] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Abstract
BACKGROUND The mixing test is used to identify the pathway to follow-up testing and is also useful for the investigation of lupus anticoagulant (LA) positivity. "To completely correct" indicates clotting factor deficiency, while "to not correct" indicates the presence of a clotting factor inhibitor including LA. "Index of circulation anticoagulant" and/or "percent correction" is used to interpret the results of mixing studies, but it does not accurately differentiate factor inhibitors from LA. AIM To precisely differentiate hemophilia A (HA), HA with inhibitor (HA-inh), and LA using the clot waveform analysis (CWA)-based mixing test. METHODS Plasma samples from HA, LA, and HA-inh including acquired HA were incubated with normal plasma in 9:1, 1:1, and 1:9 mix ratios. From activated partial thromboplastin time CWA at 0-minute (immediately) and 12-minute incubation, the ratios of CWA parameters at 12 minutes/0 minute (inhibitor index) were assessed. RESULTS The inhibitor index values of CWA parameters obtained using the mixing test in a 1:1 ratio demonstrated a significant difference between HA-inh and LA but could not differentiate LA from HA-inh completely. Plasmas used for the mixing tests in 9:1 and 1:9 ratios were able to fully distinguish between HA-inh (>0.5 BU/mL) and LA. These indices significantly correlated with inhibitor titer below 40 BU/mL (r > 0.90), possibly estimating FVIII inhibitor titer from the inhibitor index. Plasmas in HA and LA could be distinguished by mixing in a 1:1 ratio at 0 minute (immediately). CONCLUSION The inhibitor index from CWA-based mixing tests with a 12-minute incubation could differentiate among HA, HA-inh, and LA quickly.
Collapse
Affiliation(s)
- Naruto Shimonishi
- Department of Pediatrics, Nara Medical University, Kashihara, Nara, Japan
| | - Kenichi Ogiwara
- Department of Pediatrics, Nara Medical University, Kashihara, Nara, Japan
| | - Yukio Oda
- SEKISUI MEDICAL CO., LTD., Tokyo, Japan
| | | | - Mari Emmi
- SEKISUI MEDICAL CO., LTD., Tokyo, Japan
| | - Midori Shima
- Department of Pediatrics, Nara Medical University, Kashihara, Nara, Japan
| | - Keiji Nogami
- Department of Pediatrics, Nara Medical University, Kashihara, Nara, Japan
| |
Collapse
|
8
|
Shimonishi N, Ogiwara K, Oda Y, Kawabe T, Okazaki S, Shima M, Nogami K. A Novel Assessment of Factor VIII Activity by Template Matching Utilizing Weighted Average Parameters from Comprehensive Clot Waveform Analysis. Thromb Haemost 2020; 121:164-173. [PMID: 32828071 DOI: 10.1055/s-0040-1715838] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
BACKGROUND Activated partial thromboplastin time (aPTT)-based clot waveform analysis is used to evaluate the comprehensive dynamics of fibrin clot formation. In addition, the technique can be usefully utilized for the rapid assessment of factor (F)VIII procoagulant activity in various clinical settings in patients with hemophilia A (HA). We defined a novel algorithm based on the weighted average parameters from aPTT-based waveforms to devise a template-matching procedure for assessing FVIII activity (FVIII:C). METHODS The first derivatives of original clot waveforms triggered by the aPTT reagent (Coagpia APTT-N) were used to determine weighted averages of areas surrounded by the waveform at different percentages of maximum height in various clotting factor-deficient plasmas. Prepared templates based on 50 weighted average-related parameters were compared with 78 aPTT-prolonged plasmas. RESULTS Original nonsmoothed waveforms of the various clotting factor-deficient plasmas with prolonged aPTTs demonstrated a variety of shapes. The weighted averages were calculated after adjustments for different baselines, and the patterns seemed to be governed by the specific clotting factor deficiency. The weighted average-related parameters including baseline wedge (r 2 = 0.998) and aspect ratio (r 2 = 0.998) were highly correlated with FVIII:C levels. Template-matching analyses based on weighted average-related waveform parameters obtained from 158 samples demonstrated that the sensitivity was 97.2% and specificity was 83.3% in aPTT-prolonged plasmas (n = 78). CONCLUSION This novel algorithm based on weighted averages of aPTT-based waveforms together with template-matching may support clinical usefulness for judging of HA and may aid clinical management in the patients in the absence of specific clotting factor assays.
Collapse
Affiliation(s)
- Naruto Shimonishi
- Department of Pediatrics, Nara Medical University, Kashihara, Nara, Japan
| | - Kenichi Ogiwara
- Department of Pediatrics, Nara Medical University, Kashihara, Nara, Japan
| | - Yukio Oda
- Sekisui Medical Co., Ltd., Tokyo, Japan
| | | | | | - Midori Shima
- Department of Pediatrics, Nara Medical University, Kashihara, Nara, Japan
| | - Keiji Nogami
- Department of Pediatrics, Nara Medical University, Kashihara, Nara, Japan
| |
Collapse
|
9
|
Seki Y, Oda Y, Sugaya N. Very high sensitivity of a rapid influenza diagnostic test in adults and elderly individuals within 48 hours of the onset of illness. PLoS One 2020; 15:e0231217. [PMID: 32374728 PMCID: PMC7202626 DOI: 10.1371/journal.pone.0231217] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2019] [Accepted: 03/18/2020] [Indexed: 11/18/2022] Open
Abstract
During influenza epidemics, Japanese clinicians routinely perform rapid influenza diagnostic tests (RIDTs) in the examination of patients who have an influenza-like illness, and patients with positive test results, including otherwise healthy individuals, are treated with anti-influenza drugs. However, it was recently reported that the sensitivity of RIDTs was extremely low in adult patients. We examined the sensitivity and specificity of an RIDT that is widely used in Japan, ImunoAce Flu (TAUNS, Shizuoka, Japan), in comparison to reverse transcriptase polymerase chain reaction (RT-PCR). The sensitivity and specificity of the ImunoAce Flu test were 97.1% (95%CI: 93.8–98.9) and 89.2% (95%CI: 84.1–93.1), respectively. The ImunoAce Flu test is designed to not only detect influenza A or B, but also to detect H1N1pdm09 with the use of an additional test kit (Linjudge FluA/pdm). Its sensitivity and specificity for A/H1N1pdm09 were 97.6% (95%CI: 87.4–99.9) and 92.6% (95%CI: 82.1–97.9), respectively. Thus, by consecutively testing patients with the ImunoAce Flu test followed by the Linjudge FluA/pdm test, we are able to diagnose whether a patient has A/H1N1pdm09 or A/H3N2 infection within a short time. The reliability of rapid test results seems to be much higher in Japan than in other countries, because approximately 90% of influenza patients are tested and treated within 48 hours after the onset of illness, when the influenza viral load in the upper respiratory tract is high. From the Japanese experience, RIDTs are sufficiently sensitive and highly useful, if patients are tested within 48 hours after the onset of illness.
Collapse
MESH Headings
- Adult
- Age Factors
- Aged
- Aged, 80 and over
- Diagnostic Tests, Routine/methods
- Diagnostic Tests, Routine/standards
- Female
- Humans
- Immunoassay/methods
- Immunoassay/standards
- Influenza A Virus, H1N1 Subtype/genetics
- Influenza A Virus, H1N1 Subtype/immunology
- Influenza A Virus, H3N2 Subtype/genetics
- Influenza A Virus, H3N2 Subtype/immunology
- Influenza, Human/blood
- Influenza, Human/diagnosis
- Influenza, Human/epidemiology
- Influenza, Human/immunology
- Japan
- Male
- Mass Screening/methods
- Mass Screening/standards
- Middle Aged
- Reproducibility of Results
- Reverse Transcriptase Polymerase Chain Reaction
- Sensitivity and Specificity
- Time Factors
Collapse
Affiliation(s)
- Yuki Seki
- Department of Internal Medicine, Keiyu Hospital, Yokohama, Japan
| | - Yukio Oda
- Department of Clinical Laboratory, Keiyu Hospital, Yokohama, Japan
| | - Norio Sugaya
- Department of Pediatrics, Keiyu Hospital, Yokohama, Japan
- * E-mail:
| |
Collapse
|
10
|
Mizuno M, Fukunaga A, Washio K, Imamura S, Oda Y, Nishigori C. A visual analogue scale for itch and pain in 23 cases of cholinergic urticaria. J Eur Acad Dermatol Venereol 2020; 34:e493-e495. [PMID: 32242985 DOI: 10.1111/jdv.16410] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2019] [Revised: 02/12/2020] [Accepted: 03/17/2020] [Indexed: 12/15/2022]
Affiliation(s)
- M Mizuno
- Division of Dermatology, Department of Internal Related, Kobe University Graduate School of Medicine, Kobe, Japan
| | - A Fukunaga
- Division of Dermatology, Department of Internal Related, Kobe University Graduate School of Medicine, Kobe, Japan
| | - K Washio
- Division of Dermatology, Department of Internal Related, Kobe University Graduate School of Medicine, Kobe, Japan
| | - S Imamura
- Division of Dermatology, Department of Internal Related, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Y Oda
- Division of Dermatology, Department of Internal Related, Kobe University Graduate School of Medicine, Kobe, Japan
| | - C Nishigori
- Division of Dermatology, Department of Internal Related, Kobe University Graduate School of Medicine, Kobe, Japan
| |
Collapse
|
11
|
Kizawa R, Miura Y, Oda Y, Nagaoka Y, Masuda J, Ozaki Y, Kondoh C, Moriguchi S, Takahashi Y, Ogawa K, Hashimoto YT, Taniguchi S, Okaneya T, Kishi A, Hayashi N, Takaya H, Takano T. Eosinophilia during treatment of immune checkpoint inhibitors (ICIs) predicts succeeding onset of immune-related adverse events (irAEs). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz253.071] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
12
|
Oki R, Hidaka S, Moriya H, Miyake K, Oda Y, Matsui K, Taguchi S, Mochida Y, Ishioka K, Ohtake T, Kobayashi S. Remarkable Improvement of Cardiac Function After Pre-emptive Kidney Transplant in a Patient With Severe Mitral Regurgitation Accompanied by Low Cardiac Function: A Case Report. Transplant Proc 2019; 51:548-550. [PMID: 30879587 DOI: 10.1016/j.transproceed.2018.12.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2018] [Accepted: 12/09/2018] [Indexed: 10/27/2022]
Abstract
Patients with end-stage renal disease are at a high risk for cardiovascular diseases. It is controversial whether end-stage renal disease patients with low cardiac function can safely accept kidney transplant. Here, we present a 42-year-old kidney transplant recipient with severe mitral regurgitation accompanied by low cardiac function. He wanted to undergo a pre-emptive kidney transplant from his uncle. We decided to perform living kidney transplant prior to cardiac surgery. Despite adequate ultrafiltration and hemodiafiltration before operation, the patient's ejection fraction still remained 35% 1 day before transplant. He showed complete recovery of cardiac function in only 2 days after pre-emptive kidney transplant, although his body weight did not change before and after the operation. Early removal of the uremic toxin or inflammatory cytokines may play a role in rapid improvement of the cardiac function. Increase of vasoactive substances by improvement of kidney function may lead to reduction of afterload and amelioration of cardiac microcirculation. This report also suggests that optimal timing for operation might be important.
Collapse
Affiliation(s)
- R Oki
- Department of Kidney Disease and Transplant Center, Shonan Kamakura General Hospital, Kamakura, Japan.
| | - S Hidaka
- Department of Kidney Disease and Transplant Center, Shonan Kamakura General Hospital, Kamakura, Japan
| | - H Moriya
- Department of Kidney Disease and Transplant Center, Shonan Kamakura General Hospital, Kamakura, Japan
| | - K Miyake
- Department of Kidney transplant surgery, Shonan Kamakura General Hospital, Kamakura, Japan
| | - Y Oda
- Department of Kidney Disease and Transplant Center, Shonan Kamakura General Hospital, Kamakura, Japan
| | - K Matsui
- Department of Kidney Disease and Transplant Center, Shonan Kamakura General Hospital, Kamakura, Japan
| | - S Taguchi
- Department of Kidney Disease and Transplant Center, Shonan Kamakura General Hospital, Kamakura, Japan
| | - Y Mochida
- Department of Kidney Disease and Transplant Center, Shonan Kamakura General Hospital, Kamakura, Japan
| | - K Ishioka
- Department of Kidney Disease and Transplant Center, Shonan Kamakura General Hospital, Kamakura, Japan
| | - T Ohtake
- Department of Kidney Disease and Transplant Center, Shonan Kamakura General Hospital, Kamakura, Japan
| | - S Kobayashi
- Department of Kidney Disease and Transplant Center, Shonan Kamakura General Hospital, Kamakura, Japan
| |
Collapse
|
13
|
Mori H, Kubo M, Kai M, Kurata K, Kawaji H, Kaneshiro K, Motoyama Y, Kuroki R, Yamada M, Nishimura R, Okido M, Oda Y, Nakamura M. Abstract P4-06-22: Transcription factor T-bet and PD-L1 expression in tumor microenvironment of triple-negative breast cancer. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p4-06-22] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Many analyzes regarding immunotherapies using checkpoint blockade has made it clear that tumor infiltrating lymphocytes (TILs) plays an important role in treating cancers with high levels of somatic mutations such as triple-negative breast cancer (TNBC). We reported the relationship between TILs and PD-L1 expression, and revealed that high-TILs/positive-PD-L1 expression population in TNBC was associated with better prognosis (Oncotarget 2017). However, its molecular mechanism is still unclear. Meanwhile, T-box transcription factor 21 (T-bet) which regulates effecter T-cells activation is derived by stimulation of T-cell receptor and IL-12. Activated T-cells work as antitumor lymphocytes by enhancing the production of cytokines such as INFγ. We focused on T-bet and examined the function of activated T-cells.
Patients and Methods: This study included 242 patients with primary TNBC who underwent resection without neoadjuvant chemotherapy at our three hospitals between January 2004 and December 2014. The immunohistochemistry scoring for CD8 and T-bet expression on TILs was defined as ≥30 per 0.00625mm2. PD-L1 positivity was defined as ≥1% of tumor cells staining positive for PD-L1.
Results: Of the 242 TNBC, CD8 on TILs was expressed as positive in 127 (52.5%) tumors, T-bet on TILs was expressed as positive in 67 (27.7%) tumors, and PD-L1 expression on tumor cells was expressed as positive in 99 (40.9%) tumors. T-bet expression was significantly correlated with CD8 expression (P<0.0001) and PD-L1 expression (P=0.0004). There was no significant difference in recurrence free survival (RFS) and overall survival (OS) regardless of CD8 or PD-L1expression level. Meanwhile, the patients with T-bet-positive tumors had a longer OS, compared to those with T-bet-negative tumors (P = 0.13 in RFS and P = 0.047 in OS). The multivariate analysis revealed that T-bet expression on TILswas an independent and positive prognostic factor for OS(HR = 0.5, 95%CI 0.1-0.9, P = 0.035).
Conclusion: OS was significantly longer among patients with high T-bet expressing TNBC. These results may validate the significance of T-bet as a biomarker for various immunotherapies in TNBC.
Citation Format: Mori H, Kubo M, Kai M, Kurata K, Kawaji H, Kaneshiro K, Motoyama Y, Kuroki R, Yamada M, Nishimura R, Okido M, Oda Y, Nakamura M. Transcription factor T-bet and PD-L1 expression in tumor microenvironment of triple-negative breast cancer [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P4-06-22.
Collapse
Affiliation(s)
- H Mori
- Kyushu University, Fukuoka, Japan; Breast Center, Kumamoto Shinto General Hospital, Kumamoto, Japan; Breast Center, Hamanomachi Hospital, Fukuoka, Japan
| | - M Kubo
- Kyushu University, Fukuoka, Japan; Breast Center, Kumamoto Shinto General Hospital, Kumamoto, Japan; Breast Center, Hamanomachi Hospital, Fukuoka, Japan
| | - M Kai
- Kyushu University, Fukuoka, Japan; Breast Center, Kumamoto Shinto General Hospital, Kumamoto, Japan; Breast Center, Hamanomachi Hospital, Fukuoka, Japan
| | - K Kurata
- Kyushu University, Fukuoka, Japan; Breast Center, Kumamoto Shinto General Hospital, Kumamoto, Japan; Breast Center, Hamanomachi Hospital, Fukuoka, Japan
| | - H Kawaji
- Kyushu University, Fukuoka, Japan; Breast Center, Kumamoto Shinto General Hospital, Kumamoto, Japan; Breast Center, Hamanomachi Hospital, Fukuoka, Japan
| | - K Kaneshiro
- Kyushu University, Fukuoka, Japan; Breast Center, Kumamoto Shinto General Hospital, Kumamoto, Japan; Breast Center, Hamanomachi Hospital, Fukuoka, Japan
| | - Y Motoyama
- Kyushu University, Fukuoka, Japan; Breast Center, Kumamoto Shinto General Hospital, Kumamoto, Japan; Breast Center, Hamanomachi Hospital, Fukuoka, Japan
| | - R Kuroki
- Kyushu University, Fukuoka, Japan; Breast Center, Kumamoto Shinto General Hospital, Kumamoto, Japan; Breast Center, Hamanomachi Hospital, Fukuoka, Japan
| | - M Yamada
- Kyushu University, Fukuoka, Japan; Breast Center, Kumamoto Shinto General Hospital, Kumamoto, Japan; Breast Center, Hamanomachi Hospital, Fukuoka, Japan
| | - R Nishimura
- Kyushu University, Fukuoka, Japan; Breast Center, Kumamoto Shinto General Hospital, Kumamoto, Japan; Breast Center, Hamanomachi Hospital, Fukuoka, Japan
| | - M Okido
- Kyushu University, Fukuoka, Japan; Breast Center, Kumamoto Shinto General Hospital, Kumamoto, Japan; Breast Center, Hamanomachi Hospital, Fukuoka, Japan
| | - Y Oda
- Kyushu University, Fukuoka, Japan; Breast Center, Kumamoto Shinto General Hospital, Kumamoto, Japan; Breast Center, Hamanomachi Hospital, Fukuoka, Japan
| | - M Nakamura
- Kyushu University, Fukuoka, Japan; Breast Center, Kumamoto Shinto General Hospital, Kumamoto, Japan; Breast Center, Hamanomachi Hospital, Fukuoka, Japan
| |
Collapse
|
14
|
Affiliation(s)
- Y Kadoya
- Department of Cardiovascular Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kajii-cho 465, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto, Japan
- Department of Cardiovascular Medicine, Kyotango City Yasaka Hospital, Kyoto, Japan
| | - T Kenzaka
- Division of Community Medicine and Career Development, Kobe University Graduate School of Medicine, Arata-cho 2-1-5, Hyogo-ku, Kobe, Japan
| | - Y Oda
- Department of Cardiovascular Medicine, Kyotango City Yasaka Hospital, Kyoto, Japan
| | - S Matoba
- Department of Cardiovascular Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kajii-cho 465, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto, Japan
| |
Collapse
|
15
|
Saeki K, Onishi H, Oda Y, Nakamura M. FAM115c that upregulates proliferation and invasion under hypoxia could be a predictive biomarker for pancreatic cancer. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy304.034] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
16
|
Yamada Y, Toyokawa G, Tagawa T, Kamitani T, Yamasaki Y, Shoji F, Yamazaki K, Takeo S, Oda Y. Computed tomography features of resected lung adenocarcinomas with spread through air spaces. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy301.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
17
|
Toyokawa G, Takada K, Hamamoto R, Yamada Y, Tagawa T, Shoji F, Yamazaki K, Oda Y, Takeo S. A positive correlation between the EZH2 and PD-L1 expression in patients with resected lung adenocarcinoma. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy290.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
18
|
Aoki K, Shinoda M, Oda Y, Yamashita K, Matsui J, Nishio M. Absolute reliability of ultrasound assessment in measuring tibiofibular separation. Ann Phys Rehabil Med 2018. [DOI: 10.1016/j.rehab.2018.05.1031] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
19
|
Ito T, Kohashi K, Yamada Y, Furue M, Oda Y. 1179 Prognostic significance of FOXM1 expression and antitumor effect of FOXM1 inhibition in melanoma. J Invest Dermatol 2018. [DOI: 10.1016/j.jid.2018.03.1194] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
20
|
Hino H, Oda Y, Yoshida Y, Suzuki T, Shimada M, Nishikawa K. Electrophysiological effects of desflurane in children with Wolff-Parkinson-White syndrome: a randomized crossover study. Acta Anaesthesiol Scand 2018; 62:159-166. [PMID: 29068040 DOI: 10.1111/aas.13023] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2017] [Revised: 09/24/2017] [Accepted: 10/01/2017] [Indexed: 11/26/2022]
Abstract
BACKGROUND We hypothesized that, compared with propofol, desflurane prolongs the antegrade accessory pathway effective refractory period (APERP) in children undergoing radiofrequency catheter ablation for Wolff-Parkinson-White (WPW) syndrome. METHODS In this randomized crossover study, children aged 4.1-16.1 years undergoing radiofrequency catheter ablation for WPW syndrome were randomly divided into four groups according to the concentration of desflurane and anesthetics used in the first and the second electrophysiological studies (EPS). After induction of general anesthesia with propofol and tracheal intubation, they received one of the following regimens: 0.5 minimum alveolar concentration (MAC) desflurane (first EPS) and propofol (second EPS) (Des0.5-Prop group, n = 8); propofol (first EPS) and 0.5 MAC desflurane (second EPS) (Prop-Des0.5 group, n = 9); 1 MAC desflurane (first EPS) and propofol (second EPS) (Des1.0-Prop group, n = 10); propofol (first EPS) and 1 MAC desflurane (second EPS) (Prop-Des1.0 group, n = 9). Radiofrequency catheter ablation was performed upon completion of EPS. Sample size was determined to detect a difference in the APERP. RESULTS Desflurane at 1.0 MAC significantly prolonged the APERP compared with propofol, but did not affect the sinoatrial conduction time, atrio-His interval or atrioventricular node effective refractory period. Supraventricular tachycardia was induced in all children receiving propofol, but not induced in 1 and 4 children receiving 0.5 MAC and 1.0 MAC desflurane, respectively. CONCLUSION Desflurane enhances the refractoriness and may block the electrical conduction of the atrioventricular accessory pathway, and is therefore not suitable for use in children undergoing radiofrequency catheter ablation for WPW syndrome.
Collapse
Affiliation(s)
- H. Hino
- Department of Anesthesiology; Osaka City General Hospital; Osaka Japan
| | - Y. Oda
- Department of Anesthesiology; Osaka City General Hospital; Osaka Japan
| | - Y. Yoshida
- Department of Pediatric Electrophysiology; Pediatric Medical Care Center; Osaka City General Hospital; Osaka Japan
| | - T. Suzuki
- Department of Pediatric Electrophysiology; Pediatric Medical Care Center; Osaka City General Hospital; Osaka Japan
| | - M. Shimada
- Department of Anesthesiology; Osaka City Juso Hospital; Osaka Japan
| | - K. Nishikawa
- Department of Anesthesiology; Osaka City University Graduate School of Medicine; Osaka Japan
| |
Collapse
|
21
|
Harimoto N, Yugawa K, Ikegami T, Ohira M, Mano Y, Motomura T, Toshima T, Itoh S, Harada N, Soejima Y, Yoshizumi T, Maehara Y, Oda Y. Hepatobiliary and Pancreatic: Pregnancy induced hepatic veno-occlusive disease requiring liver transplantation. J Gastroenterol Hepatol 2018; 33:9. [PMID: 29284078 DOI: 10.1111/jgh.13975] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/09/2022]
Affiliation(s)
- N Harimoto
- Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - K Yugawa
- Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.,Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - T Ikegami
- Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - M Ohira
- Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - Y Mano
- Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - T Motomura
- Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - T Toshima
- Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - S Itoh
- Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - N Harada
- Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - Y Soejima
- Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - T Yoshizumi
- Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - Y Maehara
- Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - Y Oda
- Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| |
Collapse
|
22
|
Kozuma Y, Takada K, Toyokawa G, Kohashi K, Shimokawa M, Kinoshita F, Matsubara T, Haratake N, Takamori S, Akamine T, Hirai F, Tagawa T, Oda Y, Maehara Y. OA 13.06 Co-Expression of IDO1 and PD-L1 Indicates More Aggressive Features of Lung Adenocarcinoma. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.405] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
23
|
Takada K, Okamoto T, Toyokawa G, Kozuma Y, Matsubara T, Haratake N, Akamine T, Takamori S, Katsura M, Shoji F, Oda Y, Maehara Y. P1.07-002 The Expression of PD-L1 Protein as a Prognostic Factor in Lung Squamous Cell Carcinoma. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.920] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
24
|
Akamine T, Takada K, Toyokawa G, Kinoshita F, Matsubara T, Kozuma Y, Haratake N, Takamori S, Hirai F, Tagawa T, Okamoto T, Yoneshima Y, Okamoto I, Shimokawa M, Oda Y, Nakanishi Y, Maehara Y. P1.07-014 Association of Preoperative Serum CRP with PD-L1 Expression in NSCLC: A Comprehensive Analysis of Systemic Inflammatory Markers. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.932] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
25
|
Toyokawa G, Yamada Y, Tagawa T, Kinoshita F, Kozuma Y, Matsubara T, Haratake N, Takamori S, Akamine T, Takada K, Hirai F, Oda Y, Maehara Y. P3.16-033 Significance of Spread through Air Spaces in Resected Pathological Stage I Lung Adenocarcinoma. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.1839] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
26
|
Kajiwara K, Oda Y, Takahashi K, Kasugai A, Sakamoto K. Design and Operation of TE31,12 High Power Gyrotron. Fusion Science and Technology 2017. [DOI: 10.13182/fst13-a16870] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- K. Kajiwara
- Japan Atomic Energy Agency: Mukoyama 801-1, Naka, Ibaraki, 311-0193 Japan
| | - Y. Oda
- Japan Atomic Energy Agency: Mukoyama 801-1, Naka, Ibaraki, 311-0193 Japan
| | - K. Takahashi
- Japan Atomic Energy Agency: Mukoyama 801-1, Naka, Ibaraki, 311-0193 Japan
| | - A. Kasugai
- Japan Atomic Energy Agency: Mukoyama 801-1, Naka, Ibaraki, 311-0193 Japan
| | - K. Sakamoto
- Japan Atomic Energy Agency: Mukoyama 801-1, Naka, Ibaraki, 311-0193 Japan
| |
Collapse
|
27
|
Oda Y, Ikeda R, Takahashi K, Kajiwara K, Kobayashi T, Sakamoto K, Moriyama S, Darbos C, Henderson M. Recent activities of ITER gyrotron development in QST. EPJ Web Conf 2017. [DOI: 10.1051/epjconf/201714901002] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
28
|
Rutqvist J, Barr D, Birkholzer JT, Chijimatsu M, Kolditz O, Liu Q, Oda Y, Wang W, Zhang C. Results from an International Simulation Study on Coupled Thermal, Hydrological, and Mechanical Processes near Geological Nuclear Waste Repositories. NUCL TECHNOL 2017. [DOI: 10.13182/nt08-a3974] [Citation(s) in RCA: 48] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- J. Rutqvist
- Lawrence Berkeley National Laboratory, Earth Sciences Division, MS 90-1116 Berkeley, California 94720
| | - D. Barr
- U.S. Department of Energy, Office of Repository Development, Las Vegas, Nevada
| | - J. T. Birkholzer
- Lawrence Berkeley National Laboratory, Earth Sciences Division, MS 90-1116 Berkeley, California 94720
| | | | - O. Kolditz
- University of Tübingen, Tübingen, Germany
| | | | - Y. Oda
- Japan Atomic Energy Agency, Tokai, Japan
| | | | | |
Collapse
|
29
|
Gandini F, Bigelow TS, Becket B, Caughman JB, Cox D, Darbos C, Gassmann T, Henderson MA, Jean O, Kajiwara K, Kobayashi N, Nazare C, Oda Y, Omori T, Purohit D, Rasmussen DA, Ronden DMS, Saibene G, Sakamoto K, Shapiro MA, Takahashi K, Temkin RJ. The EC H&CD Transmission Line for ITER. Fusion Science and Technology 2017. [DOI: 10.13182/fst05-38] [Citation(s) in RCA: 41] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- F. Gandini
- ITER Organization, CS 90 046 - 13067 Saint Paul Lez Durance Cedex, France
| | - T. S. Bigelow
- U.S. ITER Project Office, ORNL, 1055 Commerce Park, Oak Ridge, Tennessee 37831
| | - B. Becket
- ITER Organization, CS 90 046 - 13067 Saint Paul Lez Durance Cedex, France
| | - J. B. Caughman
- U.S. ITER Project Office, ORNL, 1055 Commerce Park, Oak Ridge, Tennessee 37831
| | - D. Cox
- ITER Organization, CS 90 046 - 13067 Saint Paul Lez Durance Cedex, France
| | - C. Darbos
- ITER Organization, CS 90 046 - 13067 Saint Paul Lez Durance Cedex, France
| | - T. Gassmann
- ITER Organization, CS 90 046 - 13067 Saint Paul Lez Durance Cedex, France
| | - M. A. Henderson
- ITER Organization, CS 90 046 - 13067 Saint Paul Lez Durance Cedex, France
| | - O. Jean
- ITER Organization, CS 90 046 - 13067 Saint Paul Lez Durance Cedex, France
| | - K. Kajiwara
- Japan Atomic Energy Agency, 801-1 Mukoyama, Naka-shi, Ibaraki 311-0193, Japan
| | - N. Kobayashi
- Japan Atomic Energy Agency, 801-1 Mukoyama, Naka-shi, Ibaraki 311-0193, Japan
| | - C. Nazare
- Assystem Facilities, 23 Place de Wicklow CS 30713, 78067 Saint Quentin en Yvelines Cedex, France
| | - Y. Oda
- Japan Atomic Energy Agency, 801-1 Mukoyama, Naka-shi, Ibaraki 311-0193, Japan
| | - T. Omori
- ITER Organization, CS 90 046 - 13067 Saint Paul Lez Durance Cedex, France
| | - D. Purohit
- ITER Organization, CS 90 046 - 13067 Saint Paul Lez Durance Cedex, France
| | - D. A. Rasmussen
- U.S. ITER Project Office, ORNL, 1055 Commerce Park, Oak Ridge, Tennessee 37831
| | - D. M. S. Ronden
- Association EURATOM-FOM, 3430 BE Nieuwegein, The Netherlands
| | - G. Saibene
- Fusion for Energy, C/Josep Pla 2, Torres Diagonal Litoral-B3, E-08019 Barcelona, Spain
| | - K. Sakamoto
- Japan Atomic Energy Agency, 801-1 Mukoyama, Naka-shi, Ibaraki 311-0193, Japan
| | - M. A. Shapiro
- MIT Plasma Science and Fusion Center, Cambridge, Massachusetts 02139
| | - K. Takahashi
- Japan Atomic Energy Agency, 801-1 Mukoyama, Naka-shi, Ibaraki 311-0193, Japan
| | - R. J. Temkin
- MIT Plasma Science and Fusion Center, Cambridge, Massachusetts 02139
| |
Collapse
|
30
|
Yang HL, Kwak JG, Oh YK, Park KR, Kim WC, Lee SG, Kim JY, Bae YS, Park YM, Kim HK, Chu Y, Park MK, Kim JS, In SR, Joung SH, Choe WH, Park HK, Hwang YS, Na YS, Park JG, Ahn JW, Park YS, Kwon M, Leuer JA, Eidietis NW, Hyatt AW, Walker M, Gorelov Y, Lohr J, Mueller D, Grisham LR, Sabbagh SA, Watanabe K, Inoue T, Sakamoto K, Oda Y, Kajiwara K, Ellis R, Hosea J, Delpech L, Hoang TT, Litaudon X, Namkung W, Cho MH. Overview of KSTAR Results in Phase-I Operation. Fusion Science and Technology 2017. [DOI: 10.13182/fst13-a19130] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- H. L. Yang
- National Fusion Research Institute, 113 Gwahangno, Yusung-Gu, Daejeon, 305-333, Korea
| | - J. G. Kwak
- National Fusion Research Institute, 113 Gwahangno, Yusung-Gu, Daejeon, 305-333, Korea
| | - Y. K. Oh
- National Fusion Research Institute, 113 Gwahangno, Yusung-Gu, Daejeon, 305-333, Korea
| | - K. R. Park
- National Fusion Research Institute, 113 Gwahangno, Yusung-Gu, Daejeon, 305-333, Korea
| | - W. C. Kim
- National Fusion Research Institute, 113 Gwahangno, Yusung-Gu, Daejeon, 305-333, Korea
| | - S. G. Lee
- National Fusion Research Institute, 113 Gwahangno, Yusung-Gu, Daejeon, 305-333, Korea
| | - J. Y. Kim
- National Fusion Research Institute, 113 Gwahangno, Yusung-Gu, Daejeon, 305-333, Korea
| | - Y. S. Bae
- National Fusion Research Institute, 113 Gwahangno, Yusung-Gu, Daejeon, 305-333, Korea
| | - Y. M. Park
- National Fusion Research Institute, 113 Gwahangno, Yusung-Gu, Daejeon, 305-333, Korea
| | - H. K. Kim
- National Fusion Research Institute, 113 Gwahangno, Yusung-Gu, Daejeon, 305-333, Korea
| | - Y. Chu
- National Fusion Research Institute, 113 Gwahangno, Yusung-Gu, Daejeon, 305-333, Korea
| | - M. K. Park
- National Fusion Research Institute, 113 Gwahangno, Yusung-Gu, Daejeon, 305-333, Korea
| | - J. S. Kim
- National Fusion Research Institute, 113 Gwahangno, Yusung-Gu, Daejeon, 305-333, Korea
| | - S. R. In
- Korea Atomic Energy Research Insititute, Daeduk-Daero 989-111, Yuseong-gu, Daejeon, 305-353, Korea
| | - S. H. Joung
- Korea Atomic Energy Research Insititute, Daeduk-Daero 989-111, Yuseong-gu, Daejeon, 305-353, Korea
| | - W. H. Choe
- Korea Advanced Institute of Science and Technology, 291 Daehak-ro, Yuseong-gu, Daejeon, 305-701, Korea
| | - H. K. Park
- Pohang Univ. of Science and Technology, 77 Cheongam-ro, Nam-gu, Pohang, Gyungbuk, 790-784, Korea
| | - Y. S. Hwang
- Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul, 151-742, Korea
| | - Y. S. Na
- Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul, 151-742, Korea
| | - J. G. Park
- Princeton Plasma Physics Lab., P.O. Box 451 Princetorn, NJ 08543-0451, USA
| | - J. W. Ahn
- Oak Ridge National Lab., 1 Bethal Valley Rd, OakRidge, TN37831, USA
| | - Y. S. Park
- Columbia Univ., James Forrestal Campus (EWA 244), P.O. Box 451, Princeton, NJ 08543, USA
| | - M. Kwon
- National Fusion Research Institute, 113 Gwahangno, Yusung-Gu, Daejeon, 305-333, Korea
| | - J. A. Leuer
- General Atomics, 3550 General Atomics Court, San Diego, CA 92121, USA
| | - N. W. Eidietis
- General Atomics, 3550 General Atomics Court, San Diego, CA 92121, USA
| | - A. W. Hyatt
- General Atomics, 3550 General Atomics Court, San Diego, CA 92121, USA
| | - M. Walker
- General Atomics, 3550 General Atomics Court, San Diego, CA 92121, USA
| | - Y. Gorelov
- General Atomics, 3550 General Atomics Court, San Diego, CA 92121, USA
| | - J. Lohr
- General Atomics, 3550 General Atomics Court, San Diego, CA 92121, USA
| | - D. Mueller
- Princeton Plasma Physics Lab., P.O. Box 451 Princetorn, NJ 08543-0451, USA
| | - L. R. Grisham
- Princeton Plasma Physics Lab., P.O. Box 451 Princetorn, NJ 08543-0451, USA
| | - S. A. Sabbagh
- Columbia Univ., James Forrestal Campus (EWA 244), P.O. Box 451, Princeton, NJ 08543, USA
| | - K. Watanabe
- Japan Atomic Energy Agency, 801-1 Mukoyama, Naka-city, Ibaraki-ken, 311-0193, Japan
| | - T. Inoue
- Japan Atomic Energy Agency, 801-1 Mukoyama, Naka-city, Ibaraki-ken, 311-0193, Japan
| | - K. Sakamoto
- Japan Atomic Energy Agency, 801-1 Mukoyama, Naka-city, Ibaraki-ken, 311-0193, Japan
| | - Y. Oda
- Japan Atomic Energy Agency, 801-1 Mukoyama, Naka-city, Ibaraki-ken, 311-0193, Japan
| | - K. Kajiwara
- Japan Atomic Energy Agency, 801-1 Mukoyama, Naka-city, Ibaraki-ken, 311-0193, Japan
| | - R. Ellis
- Princeton Plasma Physics Lab., P.O. Box 451 Princetorn, NJ 08543-0451, USA
| | - J. Hosea
- Princeton Plasma Physics Lab., P.O. Box 451 Princetorn, NJ 08543-0451, USA
| | - L. Delpech
- CEA, IFRM,13108 Saint-Paul-Lez-Durance, France
| | - T. T. Hoang
- CEA, IFRM,13108 Saint-Paul-Lez-Durance, France
| | - X. Litaudon
- CEA, IFRM,13108 Saint-Paul-Lez-Durance, France
| | - W. Namkung
- Pohang Univ. of Science and Technology, 77 Cheongam-ro, Nam-gu, Pohang, Gyungbuk, 790-784, Korea
| | - M. H. Cho
- Pohang Univ. of Science and Technology, 77 Cheongam-ro, Nam-gu, Pohang, Gyungbuk, 790-784, Korea
| | | |
Collapse
|
31
|
Takahashi K, Kajiwara K, Oda Y, Sakamoto K, Omori T, Henderson M. Development of ITER Equatorial EC Launcher Components Toward the Final Design. Fusion Science and Technology 2017. [DOI: 10.13182/fst14-830] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- K. Takahashi
- Japan Atomic Energy Agency, 801-1, Mukoyama, Naka, Ibaraki 311-0193 Japan
| | - K. Kajiwara
- Japan Atomic Energy Agency, 801-1, Mukoyama, Naka, Ibaraki 311-0193 Japan
| | - Y. Oda
- Japan Atomic Energy Agency, 801-1, Mukoyama, Naka, Ibaraki 311-0193 Japan
| | - K. Sakamoto
- Japan Atomic Energy Agency, 801-1, Mukoyama, Naka, Ibaraki 311-0193 Japan
| | - T. Omori
- Japan Atomic Energy Agency, 801-1, Mukoyama, Naka, Ibaraki 311-0193 Japan
| | - M. Henderson
- ITER Organization, Route de Vinon sur Verdon, CS 90 046, 13067 St. Paul Lez Durance Cedex, France
| |
Collapse
|
32
|
Mori H, Kubo M, Yamaguti R, Nishimura R, Osako T, Arima N, Okumura Y, Okido M, Yamada M, Kai M, Kishimoto J, Oda Y, Nakamura M. Abstract P6-07-05: PD-L1 expression and decreased tumor-infiltrating lymphocytes are associated with poor prognosis in patients with triple negative breast cancer. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p6-07-05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Tumor microenvironment has been considered to have an active role in determining the aggressiveness of tumor cells. Recently, programmed cell death ligand-1 (PD-L1) expression or tumor-infiltrating lymphocytes (TILs) are known to be an important prognostic factor of breast cancer. However, the correlation of expression of PD-L1 and TILs still remains unclear. Triple-negative breast cancer (TNBC) is a heterogeneous tumor that encompasses many different subclasses. Further identification of these subclasses is necessary in order to predict prognosis and choose appropriate treatments. Our goal was to correlate PD-L1 expression with clinicopathological features including TILs by using a large cohort of TNBCs.
Patients and Methods: This study included 248 patients with primary TNBC who underwent resection without neoadjuvant chemotherapy at our three hospitals between January 2004 and December 2014. The tumor subtypes were routinely determined immunohistochemically by using resected specimens. IHC scoring for PD-L1 expression was defined in reference to that for HER2 expression. PD-L1 positivity was defined as both IHC 2+ and IHC 3+. Cases were defined as high if stromal TILs ≥50% according to recommendations by the International TILs Working Group.
Results: Of the 248 TNBCs, PD-L1 were expressed as positive in 103 (41.5%) tumors, and TILs were highly present in 118 (47.6%) tumors. PD-L1 expression was significantly correlated with higher levels of TILs (P < 0.0001). There was no significant difference when the prognosis of the patients who had PD-L1-positive tumors was compared with that of the patients who had PD-L1-negative tumors (P = 0.56 in recurrence free survival [RFS] and P = 0.13 in overall survival [OS]). Meanwhile, the patients with high-TILs tumors had longer OS, compared to the patients with low-TILs tumors (P = 0.55 in RFS and P = 0.016 in OS). The analysis in the cross effect between PD-L1 expression and TILs using cox proportional hazards model demonstrated that the PD-L1 expression and TILs are not independent factors(P = 0.0018 in RFS and P = 0.015 in OS). The PD-L1-positive group with low-TILs had significantly shorter survival than the PD-L1-positive group with high-TILs (hazard ratio [HR] = 4.7, 95% confidence interval [CI] 1.6–12.7, P = 0.0067 in RFS; HR = 8.4, 95%CI 2.3-30.3, P = 0.0019 in OS).
Conclusions: Our data indicated that PD-L1 expression was related to higher levels of TILs, and PD-L1-positive tumors with low-TILs were associated with poor prognosis in patients with TNBCs. It is proposed that these biomarkers may be of use for predicting their prognosis and essential in the subclassification of TNBCs.
Citation Format: Mori H, Kubo M, Yamaguti R, Nishimura R, Osako T, Arima N, Okumura Y, Okido M, Yamada M, Kai M, Kishimoto J, Oda Y, Nakamura M. PD-L1 expression and decreased tumor-infiltrating lymphocytes are associated with poor prognosis in patients with triple negative breast cancer [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P6-07-05.
Collapse
Affiliation(s)
- H Mori
- Graduate School of Medical Sciences, Kyushu University, Fukuoka City, Japan; Kurume Medical Center, Kurume City, Japan; Breast Center, Kumamoto Shinto General Hospital, Kumamoto City, Japan; Kumamoto Shinto General Hospital, Kumamoto City, Japan; Kumamoto City Hospital, Kumamoto City, Japan; Hamanomachi Hospital, Fukuoka City, Japan; Faculty of Medical Sciences, Kyushu University, Fukuoka City, Japan
| | - M Kubo
- Graduate School of Medical Sciences, Kyushu University, Fukuoka City, Japan; Kurume Medical Center, Kurume City, Japan; Breast Center, Kumamoto Shinto General Hospital, Kumamoto City, Japan; Kumamoto Shinto General Hospital, Kumamoto City, Japan; Kumamoto City Hospital, Kumamoto City, Japan; Hamanomachi Hospital, Fukuoka City, Japan; Faculty of Medical Sciences, Kyushu University, Fukuoka City, Japan
| | - R Yamaguti
- Graduate School of Medical Sciences, Kyushu University, Fukuoka City, Japan; Kurume Medical Center, Kurume City, Japan; Breast Center, Kumamoto Shinto General Hospital, Kumamoto City, Japan; Kumamoto Shinto General Hospital, Kumamoto City, Japan; Kumamoto City Hospital, Kumamoto City, Japan; Hamanomachi Hospital, Fukuoka City, Japan; Faculty of Medical Sciences, Kyushu University, Fukuoka City, Japan
| | - R Nishimura
- Graduate School of Medical Sciences, Kyushu University, Fukuoka City, Japan; Kurume Medical Center, Kurume City, Japan; Breast Center, Kumamoto Shinto General Hospital, Kumamoto City, Japan; Kumamoto Shinto General Hospital, Kumamoto City, Japan; Kumamoto City Hospital, Kumamoto City, Japan; Hamanomachi Hospital, Fukuoka City, Japan; Faculty of Medical Sciences, Kyushu University, Fukuoka City, Japan
| | - T Osako
- Graduate School of Medical Sciences, Kyushu University, Fukuoka City, Japan; Kurume Medical Center, Kurume City, Japan; Breast Center, Kumamoto Shinto General Hospital, Kumamoto City, Japan; Kumamoto Shinto General Hospital, Kumamoto City, Japan; Kumamoto City Hospital, Kumamoto City, Japan; Hamanomachi Hospital, Fukuoka City, Japan; Faculty of Medical Sciences, Kyushu University, Fukuoka City, Japan
| | - N Arima
- Graduate School of Medical Sciences, Kyushu University, Fukuoka City, Japan; Kurume Medical Center, Kurume City, Japan; Breast Center, Kumamoto Shinto General Hospital, Kumamoto City, Japan; Kumamoto Shinto General Hospital, Kumamoto City, Japan; Kumamoto City Hospital, Kumamoto City, Japan; Hamanomachi Hospital, Fukuoka City, Japan; Faculty of Medical Sciences, Kyushu University, Fukuoka City, Japan
| | - Y Okumura
- Graduate School of Medical Sciences, Kyushu University, Fukuoka City, Japan; Kurume Medical Center, Kurume City, Japan; Breast Center, Kumamoto Shinto General Hospital, Kumamoto City, Japan; Kumamoto Shinto General Hospital, Kumamoto City, Japan; Kumamoto City Hospital, Kumamoto City, Japan; Hamanomachi Hospital, Fukuoka City, Japan; Faculty of Medical Sciences, Kyushu University, Fukuoka City, Japan
| | - M Okido
- Graduate School of Medical Sciences, Kyushu University, Fukuoka City, Japan; Kurume Medical Center, Kurume City, Japan; Breast Center, Kumamoto Shinto General Hospital, Kumamoto City, Japan; Kumamoto Shinto General Hospital, Kumamoto City, Japan; Kumamoto City Hospital, Kumamoto City, Japan; Hamanomachi Hospital, Fukuoka City, Japan; Faculty of Medical Sciences, Kyushu University, Fukuoka City, Japan
| | - M Yamada
- Graduate School of Medical Sciences, Kyushu University, Fukuoka City, Japan; Kurume Medical Center, Kurume City, Japan; Breast Center, Kumamoto Shinto General Hospital, Kumamoto City, Japan; Kumamoto Shinto General Hospital, Kumamoto City, Japan; Kumamoto City Hospital, Kumamoto City, Japan; Hamanomachi Hospital, Fukuoka City, Japan; Faculty of Medical Sciences, Kyushu University, Fukuoka City, Japan
| | - M Kai
- Graduate School of Medical Sciences, Kyushu University, Fukuoka City, Japan; Kurume Medical Center, Kurume City, Japan; Breast Center, Kumamoto Shinto General Hospital, Kumamoto City, Japan; Kumamoto Shinto General Hospital, Kumamoto City, Japan; Kumamoto City Hospital, Kumamoto City, Japan; Hamanomachi Hospital, Fukuoka City, Japan; Faculty of Medical Sciences, Kyushu University, Fukuoka City, Japan
| | - J Kishimoto
- Graduate School of Medical Sciences, Kyushu University, Fukuoka City, Japan; Kurume Medical Center, Kurume City, Japan; Breast Center, Kumamoto Shinto General Hospital, Kumamoto City, Japan; Kumamoto Shinto General Hospital, Kumamoto City, Japan; Kumamoto City Hospital, Kumamoto City, Japan; Hamanomachi Hospital, Fukuoka City, Japan; Faculty of Medical Sciences, Kyushu University, Fukuoka City, Japan
| | - Y Oda
- Graduate School of Medical Sciences, Kyushu University, Fukuoka City, Japan; Kurume Medical Center, Kurume City, Japan; Breast Center, Kumamoto Shinto General Hospital, Kumamoto City, Japan; Kumamoto Shinto General Hospital, Kumamoto City, Japan; Kumamoto City Hospital, Kumamoto City, Japan; Hamanomachi Hospital, Fukuoka City, Japan; Faculty of Medical Sciences, Kyushu University, Fukuoka City, Japan
| | - M Nakamura
- Graduate School of Medical Sciences, Kyushu University, Fukuoka City, Japan; Kurume Medical Center, Kurume City, Japan; Breast Center, Kumamoto Shinto General Hospital, Kumamoto City, Japan; Kumamoto Shinto General Hospital, Kumamoto City, Japan; Kumamoto City Hospital, Kumamoto City, Japan; Hamanomachi Hospital, Fukuoka City, Japan; Faculty of Medical Sciences, Kyushu University, Fukuoka City, Japan
| |
Collapse
|
33
|
Oda Y, Imai T, Shimamura K, Fukunari M, Katsurayama H, Ohnishi N, Komurasaki K. A study of RF power station for microwave rocket launch system. EPJ Web Conf 2017. [DOI: 10.1051/epjconf/201714902010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
34
|
Sonoda K, Yahata H, Okugawa K, Kaneki E, Nakatsuki K, Naka M, Terado N, Ookubo F, Oda Y, Kaku T, Kato K. Isthmic-vaginal cytological findings after a trachelectomy for early-stage cervical cancer. Cytopathology 2016; 28:243-245. [PMID: 27650701 DOI: 10.1111/cyt.12379] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- K Sonoda
- Department of Obstetrics and Gynecology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - H Yahata
- Department of Obstetrics and Gynecology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - K Okugawa
- Department of Obstetrics and Gynecology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - E Kaneki
- Department of Obstetrics and Gynecology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - K Nakatsuki
- Division of Diagnostic Pathology, Kyushu University Hospital, Fukuoka, Japan
| | - M Naka
- Division of Diagnostic Pathology, Kyushu University Hospital, Fukuoka, Japan
| | - N Terado
- Division of Diagnostic Pathology, Kyushu University Hospital, Fukuoka, Japan
| | - F Ookubo
- Division of Diagnostic Pathology, Kyushu University Hospital, Fukuoka, Japan
| | - Y Oda
- Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - T Kaku
- Department of Health Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - K Kato
- Department of Obstetrics and Gynecology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| |
Collapse
|
35
|
Saito D, Mikami T, Oda Y, Hasebe D, Nishiyama H, Saito I, Kobayashi T. Relationships among maxillofacial morphologies, bone properties, and bone metabolic markers in patients with jaw deformities. Int J Oral Maxillofac Surg 2016; 45:985-91. [DOI: 10.1016/j.ijom.2016.02.003] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/01/2015] [Revised: 10/10/2015] [Accepted: 02/09/2016] [Indexed: 10/22/2022]
|
36
|
Sujaya IN, Nocianitri KA, Aryantini NPD, Nursini W, Ramona Y, Orikasa Y, Kenji F, Urashima T, Oda Y. Identifikasi dan Karakterisasi Bakteri Asam Laktat Isolat Susu Segar Sapi Bali (IDENTIFICATION AND CHARACTERIZATION OF LACTIC ACID BACTERIA ISOLATED FROM BALI CATTLE’S RAW MILK). jveteriner 2016. [DOI: 10.19087/jveteriner.2016.17.2.155] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
37
|
Abstract
'Pulsatile flow' has been reported to reduce vascular resistance. In this study, the effect of pulsatile flow was assessed quantitatively, using perfusion of canine hindlimb. The perfusion circuit consisted of roller-type pulsatile pump (Cobe Inc., Stockert pump) and bubble oxygenator (Shiley Inc., S-070/s). Each flow curve was quantified with the mean flow rate (F) and pulse power index (PPI). PPI is derived by Fourier transformation of the flow curve and represents the degree of 'pulsation'. Vascular resistance was determined during perfusion with varied flow rate and PPI. The regression formula between vascular resistance (VR) and two parameters was obtained as follows: VR(F,PPI) = 41600x(F-1.37) -0.95+913 - PPIx{(3.99x(F-1.33)-040_0.69} where VR is measured in mmHg. min-1.kg.ml-1; F represents ml.min-1.kg -1 (range from 2.8 to 17.1); and PPI is dimensionless (range from 2.8 to 215.7). Using this formula, vascular resistance at a fixed flow rate and wave form can be predicted. When the flow rate is 6.27 ml.min-1.kg-1 and the PPI is 1466, (measured values under perfusion with own beating heart) the vascular resistance perfused by own beating heart is obtained. The results indicate that the pulsation of own beating heart contributes to a reduction in vascular resistance to 80%. It is also shown that the value of PPI which is necessary to reduce the vascular resistance to 80% is more than 1300 under the normal flow rate range.
Collapse
Affiliation(s)
- A. Sohma
- Department of Surgery Kyoto Pretectural University of Medicine
| | - K. Ohga
- Department of Surgery Kyoto Pretectural University of Medicine
| | - T. Oka
- Department of Surgery Kyoto Pretectural University of Medicine
| | - Y. Oda
- Department of Physiology, Kyoto Prefectural University of Medicine, Kyoto
| | - T. Itoh
- Department of Physiology, Kyoto Prefectural University of Medicine, Kyoto
| | - T. Morimoto
- Department of Physiology, Kyoto Prefectural University of Medicine, Kyoto
| |
Collapse
|
38
|
Hashimoto K, Mori S, Oda Y, Nakano A, Sawamura T, Akagi M. Lectin-like oxidized low density lipoprotein receptor 1-deficient mice show resistance to instability-induced osteoarthritis. Scand J Rheumatol 2016; 45:412-22. [DOI: 10.3109/03009742.2015.1135979] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Affiliation(s)
- K Hashimoto
- Department of Orthopaedic Surgery, Kindai University Faculty of Medicine, Osaka, Japan
| | - S Mori
- Department of Orthopaedic Surgery, Kindai University Faculty of Medicine, Osaka, Japan
| | - Y Oda
- Department of Orthopaedic Surgery, Kindai University Faculty of Medicine, Osaka, Japan
| | - A Nakano
- Department of Bioscience, National Cardiovascular Centre Research Institute, Osaka, Japan
| | - T Sawamura
- Department of Physiology, Shinshu University School of Medicine, Nagano, Japan
| | - M Akagi
- Department of Orthopaedic Surgery, Kindai University Faculty of Medicine, Osaka, Japan
| |
Collapse
|
39
|
Tanaka K, Tokunaga E, Inoue Y, Ueo H, Yamashita N, Sagara Y, Ohi Y, Taguchi K, Ohno S, Okano S, Kitao H, Oki E, Oda Y, Maehara Y. Abstract P5-13-05: The relationship between the expression of FOXA1 and GATA3 and the efficacy of neoadjuvant endocrine therapy. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p5-13-05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background.
The estrogen receptor (ER)/ GATA3/ Forkhead box A1 (FOXA1) network is necessary for the ERα functional signature specific to luminal type breast cancers. High expression of FOXA1 indicates a good prognosis in ER-positive breast cancer. However, little is known about the association between the expression of FOXA1 and GATA3, and the efficacy of neoadjuvant endocrine therapy (NAE). This study investigated their predictive potential for NAE and the changes of their expression after NAE.
Methods.
The expression of ER, progesterone receptor (PgR), Ki67, FOXA1, and GATA3 were analyzed by immunohistochemistry in 66 patients with hormone receptor-positive/ human epidermal growth factor receptor 2 (HER2)-negative breast cancer who had been treated with NAE between March 2003 and December 2012 at Kyushu University Hospital, National Kyushu Cancer Center, and Sagara Hospital. The association between the expression of biological marker and the efficacy of NAE, and their expression changes after NAE were evaluated.
Results.
The median age of the patients was 60 years (range, 30–84 years). Pre- and post-menopausal patients were 24 (36.4%) and 42 (63.6%). Endocrine agents that were administered are as follows: aromatase inhibitors (AIs) for 42 patients (63.6%), luteinizing hormone-releasing hormone (LHRH) agonist plus AI for 10 patients (15.2%), LHRH agonist plus tamoxifen for 13 patients (19.7%). NAE yielded a partial response (PR) in 21 patients (31.8%) and stable disease (SD) in 45 patients (68.2%). Breast conserving surgery was performed in 56 patients (84.8%) and mastectomy was performed in 10 patients (15.2%). Preoperative Endocrine Prognostic Index (PEPI) score was 0 in 10 patients (15.2%) and 1 or greater (score 1 ≤) in 56 patients (84.8%).
Pre-treatment FOXA1 expression was positively correlated with GATA3 (P = 0.0003) and PgR (P = 0.0138). Post-treatment Ki67 expression was significantly lower in tumors, which achieved PR compared with those with SD (P = 0.0007). The expression of PgR, Ki67, and FOXA1 was significantly lower in post-treatment tumors compared with those in pre-treatment samples (p < 0.0001, p < 0.0001 and p < 0.0001, respectively). The expression of PgR, Ki67, and FOXA1 was significantly reduced in both tumors with PR and those with SD (PR: P = 0.0004, P < 0.0001, and P = 0.0417, respectively; SD: P < 0.0001, P = 0.0001, and P < 0.0001, respectively). The expression of PgR, Ki67, and FOXA1 was significantly decreased in post-treatment tumors in both patients with the PEPI score 0 and those with score 1 ≤ (score 0: P = 0.0078, P = 0.0059, and P = 0.0098, respectively; score 1 ≤: P < 0.0001, P < 0.0001, and P = 0.0002, respectively). In tumors with PgR > 20%, the expression of Ki67 and FOXA1 were significantly lower in post-treatment tumors (P < 0.0001 and P < 0.0001, respectively).
Conclusions.
FOXA1 expression correlated with PgR expression, and was reduced significantly after NAE. These results suggest that blocking the effect of estrogen might reduce FOXA1 expression.
Citation Format: Tanaka K, Tokunaga E, Inoue Y, Ueo H, Yamashita N, Sagara Y, Ohi Y, Taguchi K, Ohno S, Okano S, Kitao H, Oki E, Oda Y, Maehara Y. The relationship between the expression of FOXA1 and GATA3 and the efficacy of neoadjuvant endocrine therapy. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P5-13-05.
Collapse
Affiliation(s)
- K Tanaka
- Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; Graduate School of Medical Sciences, Fukuoka, Japan; Sagara Hospital, Kagoshima, Japan; National Kyushu Cancer Centre, Fukuoka, Japan
| | - E Tokunaga
- Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; Graduate School of Medical Sciences, Fukuoka, Japan; Sagara Hospital, Kagoshima, Japan; National Kyushu Cancer Centre, Fukuoka, Japan
| | - Y Inoue
- Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; Graduate School of Medical Sciences, Fukuoka, Japan; Sagara Hospital, Kagoshima, Japan; National Kyushu Cancer Centre, Fukuoka, Japan
| | - H Ueo
- Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; Graduate School of Medical Sciences, Fukuoka, Japan; Sagara Hospital, Kagoshima, Japan; National Kyushu Cancer Centre, Fukuoka, Japan
| | - N Yamashita
- Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; Graduate School of Medical Sciences, Fukuoka, Japan; Sagara Hospital, Kagoshima, Japan; National Kyushu Cancer Centre, Fukuoka, Japan
| | - Y Sagara
- Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; Graduate School of Medical Sciences, Fukuoka, Japan; Sagara Hospital, Kagoshima, Japan; National Kyushu Cancer Centre, Fukuoka, Japan
| | - Y Ohi
- Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; Graduate School of Medical Sciences, Fukuoka, Japan; Sagara Hospital, Kagoshima, Japan; National Kyushu Cancer Centre, Fukuoka, Japan
| | - K Taguchi
- Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; Graduate School of Medical Sciences, Fukuoka, Japan; Sagara Hospital, Kagoshima, Japan; National Kyushu Cancer Centre, Fukuoka, Japan
| | - S Ohno
- Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; Graduate School of Medical Sciences, Fukuoka, Japan; Sagara Hospital, Kagoshima, Japan; National Kyushu Cancer Centre, Fukuoka, Japan
| | - S Okano
- Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; Graduate School of Medical Sciences, Fukuoka, Japan; Sagara Hospital, Kagoshima, Japan; National Kyushu Cancer Centre, Fukuoka, Japan
| | - H Kitao
- Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; Graduate School of Medical Sciences, Fukuoka, Japan; Sagara Hospital, Kagoshima, Japan; National Kyushu Cancer Centre, Fukuoka, Japan
| | - E Oki
- Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; Graduate School of Medical Sciences, Fukuoka, Japan; Sagara Hospital, Kagoshima, Japan; National Kyushu Cancer Centre, Fukuoka, Japan
| | - Y Oda
- Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; Graduate School of Medical Sciences, Fukuoka, Japan; Sagara Hospital, Kagoshima, Japan; National Kyushu Cancer Centre, Fukuoka, Japan
| | - Y Maehara
- Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; Graduate School of Medical Sciences, Fukuoka, Japan; Sagara Hospital, Kagoshima, Japan; National Kyushu Cancer Centre, Fukuoka, Japan
| |
Collapse
|
40
|
Torata N, Kubo M, Miura D, Ohuchida K, Miyazaki T, Fujimura Y, Hayakawa E, Kai M, Oda Y, Mizumoto K, Hashizume M, Nakamura M. Abstract P5-05-04: MALDI mass spectrometry imaging profile of low molecular metabolites in breast carcinoma tissues embedded in frozen tissue microarray. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p5-05-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
[Background]
Metabolomics is now widely utilized for searching disease markers or identification of new drug targets. In common method, tissue samples originated in human resected specimens are stored by formalin-fixed, paraffin-embedded (FFPE) blocks. However, these samples are inadequate to measure low molecular metabolites or lipids. Furthermore, extraction process that is required for conventional mass-spectrometry causes the loss of information on the spatial localization of the metabolites. In this study, we directly analyzed breast carcinoma tissues embedded in frozen tissue microarray (fTMA) using MALDI mass spectrometry imaging (MALDI-MSI). With our original method, we could obtain profiles of low molecular metabolite and mapping images of several tissues at one time.
[Method]
Six fTMA blocks were constructed by 119 breast tissues (carcinoma 84, normal 35) from 99 patients and sectioned at 10 um thickness. MADLI-MSI were performed by AXIMA Confidence (Shimadzu, Japan) with 9-aminoacridine as a matrix (m/z range:50∼1000, Negative Ion mode). Carcinoma and normal area in individual tissues were confirmed by H&E staining of slide grasses after MADLI-MSI analysis. Acquired MSI data were processed with the freely available software BioMap (Novartis, Switzerland).
[Result]
We could detected 1,915 peaks derive from endogenous metabolite by direct tissue MALDI-MSI analysis of breast carcinoma fTMA. Among them, 185 peaks that could be commonly detected were subjected to further analysis. Among these peaks, we could identify 18 metabolites related to energy metabolism such as ATP. By comparison of metabolite profiles obtained from carcinoma with normal tissues, we found that the energy charge (EC; which is related to ATP, ADP and AMP concentrations) and the sum of adenosine phosphate compound intensities (AXP) were significantly higher than that of normal tissue (EC; T : N = 0.56 : 0.35, AXP; 17453 : 2066, p<0.0001), but there were no significant difference with lymph node metastasis, tumor histological type and tumor size. In comparison with tumor subtype, higher EC was observed in ER(+)/ Her2(-) tumor than others but AXP showed no significant among all subtypes including Ki-67 labeling index.
[Conclusion]
A combination of fTMA and MALDI-MSI is promising approach for biomarker discovery because it can achieve high throughput metabolic mapping without obvious artifact or other problem. In this study, even though high EC value were indicated in carcinoma tissue than normal but newly biomarker candidate was indeterminate at this moment. Identification of the candidates of novel carcinoma tissue biomarker is now underway.
Citation Format: Torata N, Kubo M, Miura D, Ohuchida K, Miyazaki T, Fujimura Y, Hayakawa E, Kai M, Oda Y, Mizumoto K, Hashizume M, Nakamura M. MALDI mass spectrometry imaging profile of low molecular metabolites in breast carcinoma tissues embedded in frozen tissue microarray. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P5-05-04.
Collapse
Affiliation(s)
- N Torata
- Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; Innovation Center for Medical Redox Navigation, Kyushu University, Fukuoka, Japan; Kyushu University Hospital Cancer Center, Fukuoka, Japan; Advanced Medicine Innovation Center Kyushu University, Fukuoka, Japan
| | - M Kubo
- Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; Innovation Center for Medical Redox Navigation, Kyushu University, Fukuoka, Japan; Kyushu University Hospital Cancer Center, Fukuoka, Japan; Advanced Medicine Innovation Center Kyushu University, Fukuoka, Japan
| | - D Miura
- Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; Innovation Center for Medical Redox Navigation, Kyushu University, Fukuoka, Japan; Kyushu University Hospital Cancer Center, Fukuoka, Japan; Advanced Medicine Innovation Center Kyushu University, Fukuoka, Japan
| | - K Ohuchida
- Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; Innovation Center for Medical Redox Navigation, Kyushu University, Fukuoka, Japan; Kyushu University Hospital Cancer Center, Fukuoka, Japan; Advanced Medicine Innovation Center Kyushu University, Fukuoka, Japan
| | - T Miyazaki
- Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; Innovation Center for Medical Redox Navigation, Kyushu University, Fukuoka, Japan; Kyushu University Hospital Cancer Center, Fukuoka, Japan; Advanced Medicine Innovation Center Kyushu University, Fukuoka, Japan
| | - Y Fujimura
- Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; Innovation Center for Medical Redox Navigation, Kyushu University, Fukuoka, Japan; Kyushu University Hospital Cancer Center, Fukuoka, Japan; Advanced Medicine Innovation Center Kyushu University, Fukuoka, Japan
| | - E Hayakawa
- Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; Innovation Center for Medical Redox Navigation, Kyushu University, Fukuoka, Japan; Kyushu University Hospital Cancer Center, Fukuoka, Japan; Advanced Medicine Innovation Center Kyushu University, Fukuoka, Japan
| | - M Kai
- Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; Innovation Center for Medical Redox Navigation, Kyushu University, Fukuoka, Japan; Kyushu University Hospital Cancer Center, Fukuoka, Japan; Advanced Medicine Innovation Center Kyushu University, Fukuoka, Japan
| | - Y Oda
- Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; Innovation Center for Medical Redox Navigation, Kyushu University, Fukuoka, Japan; Kyushu University Hospital Cancer Center, Fukuoka, Japan; Advanced Medicine Innovation Center Kyushu University, Fukuoka, Japan
| | - K Mizumoto
- Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; Innovation Center for Medical Redox Navigation, Kyushu University, Fukuoka, Japan; Kyushu University Hospital Cancer Center, Fukuoka, Japan; Advanced Medicine Innovation Center Kyushu University, Fukuoka, Japan
| | - M Hashizume
- Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; Innovation Center for Medical Redox Navigation, Kyushu University, Fukuoka, Japan; Kyushu University Hospital Cancer Center, Fukuoka, Japan; Advanced Medicine Innovation Center Kyushu University, Fukuoka, Japan
| | - M Nakamura
- Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; Innovation Center for Medical Redox Navigation, Kyushu University, Fukuoka, Japan; Kyushu University Hospital Cancer Center, Fukuoka, Japan; Advanced Medicine Innovation Center Kyushu University, Fukuoka, Japan
| |
Collapse
|
41
|
Mori H, Kubo M, Yamada M, Kai M, Osako T, Nishimura R, Arima N, Okido M, Kuroki S, Oda Y, Nakamura M. Abstract P4-09-15: BRCAness and PD-L1 expression of basal-like and not basal-like triple negative breast cancer. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p4-09-15] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Triple Negative Breast Cancer (TNBC) subtype occurs in approximately 20% of all patients with breast cancer and is associated with rapid growth, early metastasis and poor prognosis compared with other subtypes. TNBCs are a heterogeneous disease entity and further subclassification is needed, but still ongoing. In this study, we assessed BRCAness, defined as shared characteristics between sporadic and BRCA1-mutated tumors, in a cohort of basal-like and non-basal-like TNBCs.
Patients and Methods: DNA was isolated from formalin-fixed paraffin-embedded tumor tissues and BRCAness status was analyzed in 262 patients with primary TNBCs resected at our three hospitals between 2004 and 2014. Classification of BRCAness was performed by using Multiple Ligation-dependent Probe Amplification (MLPA) with the probemix P376 BRCA1ness by MRC (Amsterdam, Holland). The tumor subtypes were routinely determined immunohistochemically by using resected specimens. Basal-like phenotype was defined as being positive for Epidermal Growth Factor Receptor (EGFR) and/or Cytokeratin 5/6 (CK5/6). Moreover, TNBCs were stained and analyzed for programmed cell death ligand-1 (PD-L1) expression as a target of new immune therapies.
Results: Of 262 TNBCs, 232 tumors (88.5%) was a basal-like phenotype. The results of MLPA assay showed that 159 (68.5%) of 232 tumors had a BRCAness profile. Patients with basal-like BRCAness tumors were younger than patients with basal-like non-BRCAness tumors (p<0.0001). There was no significant difference between the two groups regarding pathological stage. The basal-like BRCAness group had shorter relapse-free survival (RFS) and overall survival (OS) than the basal-like non-BRCAness group (p=0.028 and p=0.13, respectively), and anthracycline-based regimens provided greater benefit to the basal-like BRCAness group significantly (p=0.01 in RFS and p=0.007 in OS). PD-L1 was expressed in 71 (44.7%) of 159 basal-like TNBCs with BRCAness.
Conclusion: We reported the majority of basal-like TNBCs showed a BRCAness profile and PD-L1 expressed in approximately 50% of BRCAness tumors. It is known that about 30% of BRCAness tumors are BRCA1-mutated tumors. Those biomarkers are essential for subclassification of TNBCs and may offer not only platinum-based chemotherapy but also novel therapies, such as immune-targeted therapies of PD-1/PD-L1 inhibitors and PARP inhibitors, to patients with basal-like TNBCs with BRCAness.
Citation Format: Mori H, Kubo M, Yamada M, Kai M, Osako T, Nishimura R, Arima N, Okido M, Kuroki S, Oda Y, Nakamura M. BRCAness and PD-L1 expression of basal-like and not basal-like triple negative breast cancer. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P4-09-15.
Collapse
Affiliation(s)
- H Mori
- Graduate School of Medical Sciences, Kyushu University, Fukuoka City, Japan; Breast Center, Kumamoto Shinto General Hospital, Kumamoto City, Japan; Kumamoto City Hospital, Kumamoto City, Japan; Hamanomachi Hospital, Fukuoka City, Japan; Kuroki Breast Clinic, Fukuoka City, Japan
| | - M Kubo
- Graduate School of Medical Sciences, Kyushu University, Fukuoka City, Japan; Breast Center, Kumamoto Shinto General Hospital, Kumamoto City, Japan; Kumamoto City Hospital, Kumamoto City, Japan; Hamanomachi Hospital, Fukuoka City, Japan; Kuroki Breast Clinic, Fukuoka City, Japan
| | - M Yamada
- Graduate School of Medical Sciences, Kyushu University, Fukuoka City, Japan; Breast Center, Kumamoto Shinto General Hospital, Kumamoto City, Japan; Kumamoto City Hospital, Kumamoto City, Japan; Hamanomachi Hospital, Fukuoka City, Japan; Kuroki Breast Clinic, Fukuoka City, Japan
| | - M Kai
- Graduate School of Medical Sciences, Kyushu University, Fukuoka City, Japan; Breast Center, Kumamoto Shinto General Hospital, Kumamoto City, Japan; Kumamoto City Hospital, Kumamoto City, Japan; Hamanomachi Hospital, Fukuoka City, Japan; Kuroki Breast Clinic, Fukuoka City, Japan
| | - T Osako
- Graduate School of Medical Sciences, Kyushu University, Fukuoka City, Japan; Breast Center, Kumamoto Shinto General Hospital, Kumamoto City, Japan; Kumamoto City Hospital, Kumamoto City, Japan; Hamanomachi Hospital, Fukuoka City, Japan; Kuroki Breast Clinic, Fukuoka City, Japan
| | - R Nishimura
- Graduate School of Medical Sciences, Kyushu University, Fukuoka City, Japan; Breast Center, Kumamoto Shinto General Hospital, Kumamoto City, Japan; Kumamoto City Hospital, Kumamoto City, Japan; Hamanomachi Hospital, Fukuoka City, Japan; Kuroki Breast Clinic, Fukuoka City, Japan
| | - N Arima
- Graduate School of Medical Sciences, Kyushu University, Fukuoka City, Japan; Breast Center, Kumamoto Shinto General Hospital, Kumamoto City, Japan; Kumamoto City Hospital, Kumamoto City, Japan; Hamanomachi Hospital, Fukuoka City, Japan; Kuroki Breast Clinic, Fukuoka City, Japan
| | - M Okido
- Graduate School of Medical Sciences, Kyushu University, Fukuoka City, Japan; Breast Center, Kumamoto Shinto General Hospital, Kumamoto City, Japan; Kumamoto City Hospital, Kumamoto City, Japan; Hamanomachi Hospital, Fukuoka City, Japan; Kuroki Breast Clinic, Fukuoka City, Japan
| | - S Kuroki
- Graduate School of Medical Sciences, Kyushu University, Fukuoka City, Japan; Breast Center, Kumamoto Shinto General Hospital, Kumamoto City, Japan; Kumamoto City Hospital, Kumamoto City, Japan; Hamanomachi Hospital, Fukuoka City, Japan; Kuroki Breast Clinic, Fukuoka City, Japan
| | - Y Oda
- Graduate School of Medical Sciences, Kyushu University, Fukuoka City, Japan; Breast Center, Kumamoto Shinto General Hospital, Kumamoto City, Japan; Kumamoto City Hospital, Kumamoto City, Japan; Hamanomachi Hospital, Fukuoka City, Japan; Kuroki Breast Clinic, Fukuoka City, Japan
| | - M Nakamura
- Graduate School of Medical Sciences, Kyushu University, Fukuoka City, Japan; Breast Center, Kumamoto Shinto General Hospital, Kumamoto City, Japan; Kumamoto City Hospital, Kumamoto City, Japan; Hamanomachi Hospital, Fukuoka City, Japan; Kuroki Breast Clinic, Fukuoka City, Japan
| |
Collapse
|
42
|
Yamada T, Kawakami S, Yoshida Y, Kawamura H, Ohta S, Abe K, Hamada H, Dohi S, Ichizuka K, Takita H, Baba Y, Matsubara S, Mochizuki J, Unno N, Maegawa Y, Maeda M, Inubashiri E, Akutagawa N, Kubo T, Shirota T, Oda Y, Yamada T, Yamagishi E, Nakai A, Fuchi N, Masuzaki H, Urabe S, Kudo Y, Nomizo M, Sagawa N, Maeda T, Kamitomo M, Kawabata K, Kataoka S, Shiozaki A, Saito S, Sekizawa A, Minakami H. Influenza 2014–2015 among pregnant Japanese women: primiparous vs multiparous women. Eur J Clin Microbiol Infect Dis 2016; 35:665-71. [DOI: 10.1007/s10096-016-2585-0] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2015] [Accepted: 01/13/2016] [Indexed: 11/28/2022]
|
43
|
Kanazawa S, Oda Y, Maeda C, Okutani R. Age-dependent decrease in desflurane concentration for maintaining bispectral index below 50. Acta Anaesthesiol Scand 2016; 60:177-82. [PMID: 26459260 DOI: 10.1111/aas.12642] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2015] [Revised: 08/31/2015] [Accepted: 09/08/2015] [Indexed: 11/27/2022]
Abstract
BACKGROUND We examined the hypothesis that the minimum alveolar concentration of desflurane for maintaining bispectral index (BIS) below 50 (MACBIS 50 ) decreases with advance of age. METHODS Sixty young (20-30 year), middle-aged (31-65 year) and elderly (66-80 year) patients were included (n = 20, each group). Five minutes following the start of continuous intravenous administration of remifentanil at 0.25 μg/kg/min, general anaesthesia was induced with propofol 2 mg/kg and rocuronium 0.8 mg/kg to facilitate tracheal intubation. Infusion of remifentanil was stopped immediately after tracheal intubation. When BIS began to increase > 60, maintenance of anaesthesia was started with an end-tidal desflurane concentration of 4.0% and maintained for 10 min followed by 1-min assessment of BIS taken at 10-s intervals. MACBIS 50 of each age group was estimated by up-down methodology. RESULTS MACBIS 50 of desflurane in young, middle-aged and elderly patients was 4.25% end-tidal (95% confidence intervals 4.04-4.46), 3.58% (3.38-3.79) and 2.75% (2.50-3.00) respectively. MACBIS 50 was higher (P = 0.011) in young patients and lower (P = 0.012) in elderly patients than those in middle-aged patients. CONCLUSIONS Advance in age significantly decreased the concentrations of desflurane required to maintain BIS below 50. BIS reflected age-associated decrease in end-tidal concentrations of desflurane required for maintaining adequate depth of anaesthesia during resting state.
Collapse
Affiliation(s)
- S. Kanazawa
- Department of Anesthesiology; Osaka City General Hospital; Osaka Japan
| | - Y. Oda
- Department of Anesthesiology; Osaka City General Hospital; Osaka Japan
| | - C. Maeda
- Department of Anesthesiology; Osaka City General Hospital; Osaka Japan
| | - R. Okutani
- Department of Anesthesiology; Osaka City General Hospital; Osaka Japan
| |
Collapse
|
44
|
Kimura T, Wang L, Tabu K, Tsuda M, Tanino M, Maekawa A, Nishihara H, Hiraga H, Taga T, Oda Y, Tanaka S. Identification and analysis of CXCR4-positive synovial sarcoma-initiating cells. Oncogene 2015; 35:3932-43. [DOI: 10.1038/onc.2015.461] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2015] [Revised: 10/21/2015] [Accepted: 10/30/2015] [Indexed: 12/13/2022]
|
45
|
Nio K, Higashi D, Kumagai H, Arita S, Shirakawa T, Nakashima K, Shibata Y, Esaki M, Ueki T, Nakano M, Ariyama H, Kusaba H, Hirahashi M, Oda Y, Esaki T, Mitsugi K, Futami K, Akashi K, Baba E. 176P Safety analysis of chemotherapy for colitis-associated colorectal cancer in Japan. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv523.37] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
46
|
Kato Y, Toga Y, Oda Y, Kawamukai E, Hirata Y. Study of enzymatic detergents with both cleaning efficacy and disinfecting action for medical devices. Antimicrob Resist Infect Control 2015. [PMCID: PMC4474615 DOI: 10.1186/2047-2994-4-s1-p37] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
|
47
|
Takahashi K, Abe G, Kajiwara K, Oda Y, Isozaki M, Ikeda R, Sakamoto K, Omori T, Henderson M. Design modification of ITER equatorial EC launcher for electron cyclotron heating and current drive optimization. Fusion Engineering and Design 2015. [DOI: 10.1016/j.fusengdes.2015.04.058] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
48
|
Hashimoto Y, Tanaka M, Senmaru T, Okada H, Hamaguchi M, Asano M, Yamazaki M, Oda Y, Hasegawa G, Nakamura N, Fukui M. Heart rate-corrected QT interval is a novel risk marker for the progression of albuminuria in people with Type 2 diabetes. Diabet Med 2015; 32:1221-6. [PMID: 25683576 DOI: 10.1111/dme.12728] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 02/09/2015] [Indexed: 12/24/2022]
Abstract
AIMS A close association between heart rate-corrected QT interval (QTc) and albuminuria in people with Type 2 diabetes has been reported in cross sectional studies. The aim of this study was to evaluate the relationship between QTc and change in urine albumin excretion (UAE) or progression of albuminuria in people with Type 2 diabetes. METHODS We measured QTc in 251 consecutive people at baseline. We performed a 5-year follow-up cohort study to assess the relationship between QTc and change in UAE, defined as an increase of UAE/follow-up duration (year), or progression of albuminuria, defined as an increase in the category of diabetic nephropathy. RESULTS During follow-up, 23 of 151 people with normoalbuminuria and 13 of 73 people with microalbuminuria at baseline had progression of albuminuria. Multiple regression analysis demonstrated that QTc was independently associated with change in UAE (β = 0.176, P = 0.0104). Logistic regression analyses showed that QTc was a risk marker for progression of albuminuria [odds ratio per 0.01-s increase in QTc 1.35, 95% confidence interval (CI) 1.11-1.66, P = 0.0024] after adjusting for confounders. According to the receiver operator characteristic (ROC) analysis, the optimal cut-off point of QTc for progression of albuminuria was 0.418 s [area under the ROC curve 0.75 (95% CI 0.66-0.82), sensitivity = 0.86, specificity = 0.56, P < 0.0001]. CONCLUSIONS Heart rate-corrected QT interval could be a novel risk marker for progression of albuminuria in people with Type 2 diabetes.
Collapse
Affiliation(s)
- Y Hashimoto
- Department of Endocrinology and Metabolism, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto, Japan
| | - M Tanaka
- Department of Endocrinology and Metabolism, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto, Japan
| | - T Senmaru
- Department of Endocrinology and Metabolism, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto, Japan
| | - H Okada
- Division of Metabolism, Nephrology and Rheumatology, Japanese Red Cross Kyoto Daini Hospital, Kyoto, Japan
| | - M Hamaguchi
- Department of Endocrinology and Metabolism, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto, Japan
| | - M Asano
- Department of Endocrinology and Metabolism, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto, Japan
| | - M Yamazaki
- Department of Endocrinology and Metabolism, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto, Japan
| | - Y Oda
- Department of Endocrinology and Metabolism, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto, Japan
| | - G Hasegawa
- Division of Metabolism, Nephrology and Rheumatology, Japanese Red Cross Kyoto Daini Hospital, Kyoto, Japan
| | - N Nakamura
- Department of Endocrinology and Metabolism, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto, Japan
| | - M Fukui
- Department of Endocrinology and Metabolism, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto, Japan
| |
Collapse
|
49
|
Ogura Y, Kawaguchi Y, Sakai S, Yamamoto M, Kimura Y, Oda Y, Imamura N, Tsukui I. Plasma levels of vitamin D metabolites in renal diseases. Contrib Nephrol 2015; 22:18-27. [PMID: 6995016 DOI: 10.1159/000385984] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
Plasma levels of 25-OH-D, 1,25-(OH)2-D and 24,25-(OH)2-D in acute renal failure, chronic glomerulonephritis and chronic renal failure were determined by competitive protein binding assay and evaluated for the correlation with the degree of renal impairment and the influence of dialysis, renal transplantation and the administration of vitamin D and 1-alpha-OH-D3. In this study it is revealed that 25-OH-D deficiency could be normalized by the administration of vitamin D2. Plasma levels of 1,25-(OH)2-D are decreased in proportion to the degree of renal impairment and it is clearly depressed in patients, with a Ccr of 30 ml/min or less. Although biosynthesis of 24,25-(OH)2-D is not remarkably depressed, it is necessary to resolve various questions including the methods of measurement in this respect. It is also disclosed in the present study that 1-alpha-OH-D3 is faster in action than vitamin D2 when used to correct 1,25-(OH)2-D3 deficiency.
Collapse
|
50
|
Harimoto N, Wang H, Ikegami T, Takeishi K, Itoh S, Yamashita YI, Yoshizumi T, Aishima S, Shirabe K, Oda Y, Maehara Y. Education and imaging. Hepatology: Rare Stevens-Johnson syndrome and vanishing bile duct syndrome induced by acetaminophen, requiring liver transplantation. J Gastroenterol Hepatol 2015; 30:656. [PMID: 25776963 DOI: 10.1111/jgh.12849] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/09/2022]
Affiliation(s)
- N Harimoto
- Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|